Table 1 Clinicopathological features of HCC patients in training and validation cohorts
Variable | Training cohort | Validation cohort | p |
|---|---|---|---|
Median(range) age, y | 55(24–85) | 55(13–83) | 0.93 |
Gender (male/female) | 175/37 | 88/19 | 0.95 |
Tumor size(≤3,> 3), cm | 76/133 | 38/69 | 0.82 |
Vascular invasion(Present/Absent) | 22/190 | 12/95 | 0.82 |
Microvascular invasion(Present/Absent) | 68/144 | 29/78 | 0.36 |
Tumor differentiation (III-IV/I-II) | 16/193 | 6/101 | 0.46 |
Liver cirrhosis(Present/Absent) | 166/46 | 87/20 | 0.53 |
HbsAg (Positive/Negative) | 178/34 | 85/22 | 0.32 |
Tumor encapsulation (Present/ Absent) | 112/110 | 59/48 | 0.70 |
Preoperative blood test | |||
DBIL(mean ± SD), μmol/L | 6.9 ± 11.9 | 7.3 ± 16.4 | 0.45 |
TBIL(mean ± SD), μmol/L | 14.8 ± 14.5 | 15.04 ± 19.2 | 0.94 |
ALT(mean ± SD), U/L | 40.1 ± 31.3 | 46.1 ± 69.2 | 0.91 |
AST(mean ± SD), U/L | 38.7 ± 27.3 | 453.6 ± 66.3 | 0.67 |
AFP(mean ± SD), ng/ml | 4460 ± 13,186 | 3800 ± 12,646 | 0.60 |
ALB(mean ± SD), g/L | 40.7 ± 7.0 | 39.8 ± 3.6 | 0.06 |
GGT(mean ± SD), U/L | 84.3 ± 98.8 | 80.8 ± 83.5 | 0.38 |